REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Two-sample hypothesis tests are appropriate for comparing the two samples in which the samples are divided by the two control cases in the experiment. Z-tests are appropriate for comparing means under stringent conditions regarding normality and a known standard deviation. Student's t-tests are appropriate for comparing means under relaxed conditions when less is assumed. Welch's t-test assumes the least and is therefore the most commonly used two-sample hypothesis test in which the mean of a metric is to be optimized. While the mean of the variable to be optimized is the most common choice of estimator, others are regularly used. Fisher's exact test can be employed to compare two binomial distributions, such as a click-through rate.
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties" (PDF). Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Silva, Robert J. (2011). "Chapter 13. Fermium, Mendelevium, Nobelium, and Lawrencium". In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements. Netherlands: Springer. pp. 1621–1651. doi:10.1007/978-94-007-0211-0_13. ISBN 978-94-007-0210-3. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
The study of mechanical or "formal" reasoning began with philosophers and mathematicians in antiquity. The study of logic led directly to Alan Turing's theory of computation, which suggested that a machine, by shuffling symbols as simple as "0" and "1", could simulate any conceivable form of mathematical reasoning. This, along with concurrent discoveries in cybernetics, information theory and neurobiology, led researchers to consider the possibility of building an "electronic brain". They developed several areas of research that would become part of AI, such as McCulloch and Pitts design for "artificial neurons" in 1943, and Turing's influential 1950 paper 'Computing Machinery and Intelligence', which introduced the Turing test and showed that "machine intelligence" was plausible. The field of AI research was founded at a workshop at Dartmouth College in 1956. The first AI program, Logic Theorist, was presented at the workshop, created by future Turing Award winner Allen Newell and future Nobel Laureate Herbert A. Simon, in collaboration with J. C. Shaw. Many of the workshop attendees became the leaders of AI research in the 1960s. They and their students produced programs that the press described as "astonishing": computers were learning checkers strategies, solving word problems in algebra, proving logical theorems and speaking English. Artificial intelligence laboratories were set up at a number of British and U.S. universities in the latter 1950s and early 1960s.
Edvard Beneš resigned as president of the First Czechoslovak Republic on 5 October 1938 after the Nazi coup. In London, he and other Czechoslovak exiles organized a Czechoslovak government-in-exile and negotiated to obtain international recognition for the government and a renunciation of the Munich Agreement and its consequences. After World War II broke out, a Czechoslovak national committee was constituted in France, and under Beneš's presidency sought international recognition as the exiled government of Czechoslovakia. This attempt led to some minor successes, such as the French-Czechoslovak treaty of 2 October 1939, which allowed for the reconstitution of the Czechoslovak army on French territory, yet full recognition was not reached. The Czechoslovak army in France was established on 24 January 1940, and units of its 1st Infantry Division took part in the last stages of the Battle of France, as did some Czechoslovak fighter pilots in various French fighter squadrons. Beneš hoped for a restoration of the Czechoslovak state in its pre-Munich form after the anticipated Allied victory, a false hope. The government in exile—with Beneš as president of republic—was set up in June 1940 in exile in London, with the President living at Aston Abbotts. On 18 July 1940, it was recognised by the British government. Belatedly, the Soviet Union (in the summer of 1941) and the U.S. (in the winter) recognised the exiled government.
Sources: en.wikipedia.org
=== European Union === In August 2021, Foreign Minister Béjar announced Peru's withdrawal, without officially carrying it out, from the Lima Group and support for the International Contact Group of the European Union for a negotiated solution between the regime of Nicolás Maduro and the opposition regarding the Venezuelan crisis. In addition, Béjar announced his intention, as foreign minister, to reconstitute the UNASUR and strengthen the CELAC, although this was not officially carried out.In September 2021, the Peruvian government signed the "Development Objectives Grant Agreement" with the United States Agency for International Development (USAID) to receive 321 million dollars through 2026. The agreement was signed between Foreign Minister Maúrtua and Jene Thomas, USAID mission director, in the presence of U.S. ambassador Lisa Kenna, who before joining the diplomatic service had been an agent of the CIA. During that same month, the Peruvian government signed the United Nations Sustainable Development Cooperation Framework in Peru 2022-2026 for 180 million dollars, with the framework's preparation led by the resident coordinator of the United Nations System (UNS) in the country to "contribute to the efforts of the Government of Peru in fulfilling the 2030 Agenda and the Sustainable Development Goals, as well as the national development priorities with which this roadmap aligns", also establishing "the general guidelines for developing joint work plans between the Government of Peru and twenty-two AFPs [UN Agencies, Funds and Programmes]" over the following five years.
== Chemical properties == Alkanes are only weakly reactive with most chemical compounds. They only react with the strongest of electrophilic reagents by virtue of their strong C–H bonds (~100 kcal/mol) and C–C bonds (~90 kcal/mol). They are also relatively unreactive toward free radicals. This inertness is the source of the term paraffins (with the meaning here of "lacking affinity"). In crude oil the alkane molecules have remained chemically unchanged for millions of years.
Hormones during pregnancy are the result of an intricate interaction between hormones generated by different glands and organs. The primary hormones involved comprise human chorionic gonadotropin (hCG), progesterone, estrogen, human placental lactogen (hPL), and oxytocin. Hormones are synthesized in certain organs, including the ovaries, placenta, and pituitary gland. These hormones have essential functions in pregnancy test, maintaining the uterine lining, fetal development, preventing premature labor, and the initiation and support of labor. Subsequently, the hormones are stored and released into the circulation to be conveyed to the specific cells they are intended for. Once they reach the target cells, they are recognized by associated cell membrane or intracellular receptor proteins, leading to a cellular response. There are disorders related to hormonal imbalances, such as breast cancer, hyperrelaxinemia and Polycystic Ovary Syndrome (PCOS), having a significant influence on reproductive health.
==== Multicenter ESG Randomized Trial (MERIT) ==== The recently published MERIT study is the first and only randomized controlled trial of the ESG for treatment of obesity and included 209 adult subjects with class I and II obesity (BMI 30–40 kg/m2). It was conducted from Dec. 2017 to Jun. 2019, spanned nine centers in the United States, and comprised 85 adults in the ESG arm and 124 adults in the control arm (lifestyle modification only). Subjects in the ESG arm lost 13.6% of body weight and 49.2% of excess body weight at one year, compared to 0.8% total body weight loss and 3.2% excess weight loss in the control arm at the same time point.
Colloidal gold has been used by artists for centuries because of the nanoparticle's interactions with visible light. Gold nanoparticles absorb and scatter light resulting in colours ranging from vibrant reds (smaller particles) to blues to black and finally to clear and colorless (larger particles), depending on particle size, shape, local refractive index, and aggregation state. These colors occur because of a phenomenon called localized surface plasmon resonance (LSPR), in which conduction electrons on the surface of the nanoparticle oscillate in resonance with incident light.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.